Prevention & care
Blood in urine: visible bleeding, microscopic findings and assessment
On this page
Hematuria means blood in urine. Visible, or gross, hematuria can make urine pink, red or brown. Microscopic hematuria is detected by testing while urine may look ordinary. These descriptions identify how the finding is noticed, not the underlying cause.[1]
Visible blood deserves assessment even when the amount seems small
NHS advises an urgent medical appointment if you see or suspect blood in urine, including a small amount or uncertainty about whether it is blood. Tell the clinician about pain, fever, medicines and whether the apparent blood might come from the vagina or bowel. Do not diagnose the cause from color alone.[2]
Clots, impaired urination and illness change urgency
Contact medical services immediately if urinary bleeding accompanies inability to urinate, clots, fever, shaking chills, vomiting, or abdominal, side or back pain. These features can need urgent assessment of infection, obstruction or another cause. An inability to pass urine should not wait for a routine blood-in-urine appointment.[3]
Red urine and urinary bleeding are different observations
Beetroot and some medicines can change urine color; menstrual, vaginal or rectal bleeding can also be mistaken for urinary blood. NHS still advises assessment when you think blood may be present. Mention those possibilities so the source of bleeding and the specimen can be checked.[2]
The urinary tract contains several possible sources
Infection, inflammation, stones, trauma, recent procedures and an enlarged prostate can cause urinary blood. Kidney filtering disease, clotting disorders and cancers are other possibilities. Visible bleeding often has no pain, and a small quantity of blood can noticeably change color. Treatment follows the cause rather than the color itself.[1]
An asymptomatic strip finding may need confirmation
The ACP’s 2016 advice distinguishes a positive heme dipstick from red cells confirmed by microscopy before investigating asymptomatic adults. It also advises evaluation when someone takes an antiplatelet or anticoagulant: a medicine exposure should not close the diagnostic question. Discuss medicine management with the treating team rather than independently stopping prescribed protection against clots.[4]
A cancer-pathway referral is an investigation, not a diagnosis
NICE’s UK pathway includes unexplained visible urinary blood without a UTI, or visible blood that persists or recurs after successful UTI treatment, in adults aged 45 and over. These criteria guide an expedited cancer-investigation route; they are not instructions for younger people to ignore bleeding. Ask what follow-up is needed if infection is the initial explanation.[5]
Children have a separate assessment pathway
RCH guidance notes that many children with isolated, symptom-free microscopic blood need follow-up urine samples rather than immediate extensive investigation. Blood with pain, swelling, high blood pressure, protein in urine or systemic illness changes concern. A child’s assessment should include the relevant family history and examination; adult cancer-risk frameworks cannot be copied directly.[6]
A cystoscopy plan should explain preparation and aftercare
Cystoscopy uses an instrument to inspect the urethra and bladder. NIDDK advises discussing medicines, allergies, anesthesia, preparation and what happens afterward. Infection, bleeding, discomfort and urinary difficulty are possible risks. After the procedure, inability to urinate, bright-red urine or clots, fever or severe discomfort needs prompt medical contact. Follow the team’s instructions rather than one generic fasting or medicine-stop rule.[8]
Evidence & uncertainty
Testing everyone in the same way can miss differences in risk and create unnecessary investigation. A 2021 review found low cancer-detection yields across evaluated microhematuria cohorts, with higher yields in higher-risk groups. Those averages are not an individual cancer probability.[9]
Selected-source overview · Independent review pendingPublished questions
Does microscopic mean the blood is visible as tiny red specks?
Selected-source overview · Independent review pending. Read the evidence context.
No. Microscopic hematuria may leave urine looking normal and is found by testing. Visible and microscopic describe detection, not the disease causing it.[1]
Evidence behind this answer
- Hematuria (Blood in the Urine)
agency patient explanation · 2022
Relevant original source text read; no independent full evidence appraisal · Definition, symptoms, causes, assessment and cause-specific treatment
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can food or a medicine make urine look bloody?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. Beetroot and some medicines can alter color, while blood from another body site can be misleading. Seek assessment if you think urinary blood may be present.[2]
Evidence behind this answer
- Blood in urine
official patient guidance · 2026
Relevant original source text read; no independent full evidence appraisal · Urgent assessment, color changes and possible non-urinary sources
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Should blood clots or inability to pass urine wait for a routine visit?
Selected-source overview · Independent review pending. Read the evidence context.
No. Obtain immediate medical advice or urgent assessment, especially when urine will not pass. Fever, vomiting, chills or side/back pain also changes urgency.[3]
Evidence behind this answer
- Urine: bloody
official hosted clinical explanation · 2025
Relevant original source text read; no independent full evidence appraisal · When to contact a medical professional immediately: clots, inability to urinate and systemic symptoms
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does taking a blood thinner explain away urinary blood?
Selected-source overview · Independent review pending. Read the evidence context.
No. ACP advises pursuing evaluation despite antiplatelet or anticoagulant use. The cause and safe medicine plan need assessment; do not independently stop a prescribed medicine.[4]
Evidence behind this answer
- Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians
original professional advice · 2016
Original indexed complete abstract read; full journal appraisal not completed · Original complete abstract: advice3,4,5,6; confirmation and evaluation despite antithrombotics
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Is a positive blood dipstick enough to start every invasive investigation?
Selected-source overview · Independent review pending. Read the evidence context.
ACP’s adult asymptomatic pathway calls for microscopic confirmation. The result, symptoms and specimen context guide subsequent evaluation rather than the strip alone.[4]
Evidence behind this answer
- Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians
original professional advice · 2016
Original indexed complete abstract read; full journal appraisal not completed · Original complete abstract: advice3,4,5,6; confirmation and evaluation despite antithrombotics
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
What if visible urinary blood continues after UTI treatment?
Selected-source overview · Independent review pending. Read the evidence context.
Ask for reassessment rather than repeatedly assuming infection. NICE includes persistent or recurrent visible blood after successful treatment in specified adult expedited-referral criteria.[5]
Evidence behind this answer
- Suspected cancer: recognition and referral, NG12
original professional guideline · 2015
Original recommendations retrieved with Firecrawl after native403; selected urinary and colorectal statements read · 1.6.4–1.6.6: adult visible hematuria referral after exclusion or successful treatment of UTI
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does every child with microscopic urinary blood need an immediate scan?
Selected-source overview · Independent review pending. Read the evidence context.
No. RCH separates isolated symptom-free findings from blood accompanied by pain, swelling, protein, high blood pressure or illness. Follow-up and testing should be pediatric and clinician directed.[6]
Evidence behind this answer
- Clinical Practice Guidelines: Haematuria
hospital pediatric clinical guideline · 2021-04
Relevant original source text read; no independent full evidence appraisal · Isolated microscopic blood, pediatric red flags, history and follow-up
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does a normal kidney ultrasound assess everything that cystoscopy does?
Selected-source overview · Independent review pending. Read the evidence context.
No. DETECT I found different diagnostic strengths and concluded that imaging could not replace cystoscopy for bladder assessment. The appropriate tests depend on the question.[7]
Evidence behind this answer
- Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?
original prospective diagnostic cohort · 2018
Original full manuscript retrieved; abstract, population and methods read · Original abstract and methods:3556 adults, test strengths and cystoscopy distinction
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Should everyone use the same preparation for cystoscopy?
Selected-source overview · Independent review pending. Read the evidence context.
No. Anesthesia, planned sampling, infection and medicines can change instructions. Ask the team about preparation, aftercare and which symptoms require prompt contact.[8]
Evidence behind this answer
- Cystoscopy and Ureteroscopy
agency procedure explanation · 2021
Relevant original source text read; no independent full evidence appraisal · Preparation, procedure purpose, risks and urgent aftercare
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can a study’s cancer-detection rate tell me my personal risk?
Selected-source overview · Independent review pending. Read the evidence context.
No. The review combined evaluated cohorts with different characteristics and tests. Detection yield is a group result; risk factors and the clinical finding determine an individual assessment.[9]
Evidence behind this answer
- Assessment of Diagnostic Yield of Cystoscopy and Computed Tomographic Urography for Urinary Tract Cancers in Patients Evaluated for Microhematuria
systematic review meta analysis · 2021
Original full text retrieved; abstract, scope and selected interpretation read · Original abstract and scope:30 studies,24366 patients, detection yield and risk-group differences
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can a negative urine marker test replace cystoscopy for everyone?
Selected-source overview · Independent review pending. Read the evidence context.
The cited trial tested a specific marker in a defined lower-risk pathway. Its findings concern procedure use and diagnostic performance, not every assay or all hematuria populations.[10]
Evidence behind this answer
- A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: STRATA
original randomized diagnostic strategy trial · 2024
Original indexed abstract and disclosures read in full; PMC full text retrieval failed · Original complete abstract and disclosures:135 lower-risk randomized, procedure use and test performance
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Imaging and looking inside the bladder answer different questions
DETECT I was a prospective UK study of 3,556 referred adults. Ultrasound and CT had different strengths; ultrasound detected upper-tract urothelial cancer poorly, and imaging did not replace cystoscopy for bladder assessment. The study’s older referral population and definitions limit transfer to every incidental urine result. A normal kidney ultrasound is not a universal examination of the entire urinary tract.[7]
A low average detection yield still requires individual decisions
The 2021 review combined 30 studies with 24,366 people evaluated for microscopic hematuria. Pooled detection was about 2% for bladder cancer and lower for upper-tract and kidney cancers; higher-risk cohorts had higher yields. Included studies and testing intensity differed. This supports discussing the reason for each test, its limits and harms rather than converting a pooled percentage into personal reassurance.[9]
A urine-marker trial changed procedure use in a defined group
STRATA randomized 135 lower-risk participants within a 390-person microhematuria study to a marker-informed or usual-care decision. Cystoscopy occurred in 27% versus 67%; the study reported 99% negative predictive value for the tested marker overall. That value depends on the study population and does not mean every negative urine test excludes cancer. Developer employees and other commercial relationships were disclosed. The principal clinical-utility question was procedure use, not a proven reduction in cancer deaths.[10]
Guidance has changed as evidence develops
The original abstract of the 2025 AUA/SUFU amendment reports revised risk stratification and updated marker, cytology and surveillance guidance after reviewing newer evidence. Full recommendations were not accessible in this research session. The older ACP advice and one marker trial should therefore not be presented as a complete current algorithm for choosing or avoiding cystoscopy.[11]
References
- Hematuria (Blood in the Urine)
Agency patient explanation
National Institute of Diabetes and Digestive and Kidney Diseases · Content/publication date: 2022
Accessed: 2026-10-20 UTC · Relevant original source text read; no independent full evidence appraisal
Cited sections: Definition, symptoms, causes, assessment and cause-specific treatment - Blood in urine
Official patient guidance
NHS · Content/publication date: 2026
Accessed: 2026-10-20 UTC · Relevant original source text read; no independent full evidence appraisal
Cited sections: Urgent assessment, color changes and possible non-urinary sources - Urine: bloody
Official hosted clinical explanation
MedlinePlus / A.D.A.M. medical encyclopedia · Content/publication date: 2025
Accessed: 2026-10-20 UTC · Relevant original source text read; no independent full evidence appraisal
Cited sections: When to contact a medical professional immediately: clots, inability to urinate and systemic symptomsSelected urgency advice; no personal diagnosis.
- Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians
Original professional advice
Nielsen M, Qaseem A and ACP High Value Care Task Force · Content/publication date: 2016
Accessed: 2026-10-20 UTC · Original indexed complete abstract read; full journal appraisal not completed
Cited sections: Original complete abstract: advice3,4,5,6; confirmation and evaluation despite antithromboticsOlder narrative-review advice, not the 2025 AUA algorithm.
- Suspected cancer: recognition and referral, NG12
Original professional guideline
NICE · Content/publication date: 2015
Accessed: 2026-10-20 UTC · Original recommendations retrieved with Firecrawl after native403; selected urinary and colorectal statements read
Cited sections: 1.6.4–1.6.6: adult visible hematuria referral after exclusion or successful treatment of UTISpecified urinary recommendations dated 2015; whole guideline counted jointly.
- Clinical Practice Guidelines: Haematuria
Hospital pediatric clinical guideline
Royal Children’s Hospital Melbourne · Content/publication date: 2021-04
Accessed: 2026-10-20 UTC · Relevant original source text read; no independent full evidence appraisal
Cited sections: Isolated microscopic blood, pediatric red flags, history and follow-upPediatric scope; not an adult cancer-risk algorithm.
- Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?
Original prospective diagnostic cohort
Tan WS and DETECT I collaborators · Content/publication date: 2018
Accessed: 2026-10-20 UTC · Original full manuscript retrieved; abstract, population and methods read
Cited sections: Original abstract and methods:3556 adults, test strengths and cystoscopy distinctionReferred population; median age 68. Not randomized.
- Cystoscopy and Ureteroscopy
Agency procedure explanation
National Institute of Diabetes and Digestive and Kidney Diseases · Content/publication date: 2021
Accessed: 2026-10-20 UTC · Relevant original source text read; no independent full evidence appraisal
Cited sections: Preparation, procedure purpose, risks and urgent aftercare - Assessment of Diagnostic Yield of Cystoscopy and Computed Tomographic Urography for Urinary Tract Cancers in Patients Evaluated for Microhematuria
Systematic review meta analysis
Waisbrod S and colleagues · Content/publication date: 2021
Accessed: 2026-10-20 UTC · Original full text retrieved; abstract, scope and selected interpretation read
Cited sections: Original abstract and scope:30 studies,24366 patients, detection yield and risk-group differencesSearch through 2019; heterogeneity and selected evaluated cohorts.
- A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: STRATA
Original randomized diagnostic strategy trial
Lotan Y and colleagues · Content/publication date: 2024
Accessed: 2026-10-20 UTC · Original indexed abstract and disclosures read in full; PMC full text retrieval failed
Cited sections: Original complete abstract and disclosures:135 lower-risk randomized, procedure use and test performanceAbstract only; commercial relationships include developer employment.
- Updates to Microhematuria: AUA/SUFU Guideline 2025
Original guideline amendment
Barocas DA and colleagues / AUA and SUFU · Content/publication date: 2025
Accessed: 2026-10-20 UTC · Original indexed abstract read in full; main AUA page offers only purpose/key takeaways before login; full recommendations not read
Cited sections: Original complete abstract:2025 update scope, revised risk system, markers and surveillanceNo detailed 2025 threshold or marker recommendation inferred.
Scope & review
- Population
- Adults with suspected urinary blood or a microscopic finding; pediatric considerations separately labeled
- Exposure or intervention
- Recognition, specimen context, escalation, cause-specific investigation and selected test evidence
- Comparison
- Visible versus microscopic; test types and risk-specific versus uniform evaluation; trial-specific strategy comparison
- Outcomes
- Appropriate assessment, identification of cause, procedure burden and diagnostic limits
- Timeframe
- Source-specific publication, update and search dates remain separate; checked 2026-10-20 UTC
- Jurisdiction
- UK public/referral guidance, US advice and studies, Australian pediatric guidance
Targeted original-source reading and comparison with current guide bodies, tables and FAQs. Claim-linked selected recommendations and study findings are educational synthesis, not a systematic search, independent evidence grade or qualified clinical review.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-20 UTC: New symptom guide drafted after source verification, existing-scope comparison and cumulative attribution audit; qualified review pending.
What this article still leaves open
- How current risk-based algorithms and validated markers affect missed diagnoses and long-term patient outcomes.
- Cause-specific treatment and follow-up after a negative evaluation need separate appraisal.
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.